annb0t
Top 20
MELBOURNE, Australia and INDIANAPOLIS, May 30, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today provides an update on the U.S. and Australian launch and reimbursement status for its prostate cancer imaging agent, Illuccix® (kit for preparation of gallium (68Ga) gozetotide).
U.S. Launch Update: Full reimbursement in the U.S. to be effective from July 1
Telix's prostate cancer imaging agent Illuccix® has been granted Transitional Pass-Through...
>>> Read more: Illuccix® Reimbursement Milestone and Launch Updates: Pass-Through Status Granted in the U.S.
U.S. Launch Update: Full reimbursement in the U.S. to be effective from July 1
Telix's prostate cancer imaging agent Illuccix® has been granted Transitional Pass-Through...
>>> Read more: Illuccix® Reimbursement Milestone and Launch Updates: Pass-Through Status Granted in the U.S.
